comparemela.com

Latest Breaking News On - Atricure company profile get rating - Page 1 : comparemela.com

AtriCure (NASDAQ:ATRC) Lowered to Sell at StockNews com

StockNews.com cut shares of AtriCure (NASDAQ:ATRC – Get Rating) from a hold rating to a sell rating in a research note published on Friday morning. Several other research analysts have also recently commented on ATRC. Needham & Company LLC lowered their target price on AtriCure from $79.00 to $67.00 in a research note on Wednesday, […]

Analysts Anticipate AtriCure, Inc (NASDAQ:ATRC) Will Announce Quarterly Sales of $79 33 Million

Wall Street brokerages expect that AtriCure, Inc. (NASDAQ:ATRC – Get Rating) will post $79.33 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for AtriCure’s earnings. The lowest sales estimate is $78.20 million and the highest is $81.73 million. AtriCure posted sales of $71.38 million in the […]

AtriCure, Inc (NASDAQ:ATRC) Expected to Announce Earnings of -$0 32 Per Share

Analysts expect AtriCure, Inc. (NASDAQ:ATRC – Get Rating) to report earnings per share of ($0.32) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for AtriCure’s earnings, with estimates ranging from ($0.36) to ($0.28). AtriCure reported earnings per share of ($0.36) during the same quarter last year, which would […]

-$0 26 Earnings Per Share Expected for AtriCure, Inc (NASDAQ:ATRC) This Quarter

Wall Street analysts expect that AtriCure, Inc. (NASDAQ:ATRC – Get Rating) will announce ($0.26) earnings per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for AtriCure’s earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate coming in at ($0.40). AtriCure posted earnings of ($0.38) […]

AtriCure, Inc (NASDAQ:ATRC) Receives Consensus Recommendation of Buy from Brokerages

AtriCure, Inc. (NASDAQ:ATRC – Get Rating) has been given a consensus recommendation of “Buy” by the thirteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.